Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Income towards Parent Company (2023 - 2025)

CG Oncology filings provide 3 years of Income towards Parent Company readings, the most recent being -$41.3 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company fell 29.72% to -$41.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$160.8 million, a 82.69% decrease, with the full-year FY2025 number at -$160.8 million, down 82.69% from a year prior.
  • Income towards Parent Company hit -$41.3 million in Q4 2025 for CG Oncology, up from -$43.7 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$8.7 million in Q1 2023 to a low of -$43.7 million in Q3 2025.
  • Median Income towards Parent Company over the past 3 years was -$19.7 million (2024), compared with a mean of -$24.8 million.
  • The widest YoY moves for Income towards Parent Company: up 29.72% in 2025, down 119.05% in 2025.
  • CG Oncology's Income towards Parent Company stood at -$16.6 million in 2023, then crashed by 92.16% to -$31.8 million in 2024, then decreased by 29.72% to -$41.3 million in 2025.
  • The last three reported values for Income towards Parent Company were -$41.3 million (Q4 2025), -$43.7 million (Q3 2025), and -$41.4 million (Q2 2025) per Business Quant data.